XRTX Share Price Performance
CA$1.25
-0.90 (-41.86%)
Price CA$1.25
Share PriceCA$1.25
XORTX Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
XRTX Community Narratives
There are no narratives available yet.
Recent XRTX News & Updates
XORTX Therapeutics Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.36
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
XORTX Therapeutics Inc. Competitors
Snowflake Analysis
About XRTX
- Founded
- n/a
- Employees
- 3
- CEO
- WebsiteView website
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Canadian Market Performance
- 7 Days: 1.3%
- 3 Months: 11.0%
- 1 Year: 22.5%
- Year to Date: 20.2%
The market has climbed 1.3% in the last 7 days, lead by the Materials sector with a gain of 3.0%. The market is up 22% over the last 12 months. Earnings are forecast to grow by 11% annually. Market details ›